Literature DB >> 11430595

Reactivation and role of HHV-8 in Kaposi's sarcoma initiation.

B Ensoli1, M Stürzl, P Monini.   

Abstract

Kaposi's sarcoma (KS) is an angioproliferative disease occurring in several clinical-epidemio-logic forms but all associated with infection by the human herpesvirus-8 (HHV-8). At least in early stages, KS is a reactive disease associated with a state of immune dysregulation characterized by CD8+ T-cell activation and production of Th1-type inflammatory cytokines (IC) that precedes lesion development. In fact, evidence indicates that IC can trigger lesion formation by inducing the activation of endothelial cells that leads to adhesion and tissue extravasation of lymphomonocytes, spindle cell formation, and angiogenesis, and HHV-8 reactivation that, in turn, leads to virus spread to all circulating cell types and virus dissemination into tissues. Due to virus escape mechanisms and deficient immune responses toward HHV-8, virus reactivation and spread are not controlled by the immune system but induce immune responses that may paradoxically exacerbate the reactive process. The virus is recruited into "activated" tissue sites where it finds an optimal environment for growth. In fact, viral load is very low in early lesions, whereas almost all spindle cells are infected in late-stage lesions. Although early KS is a reactive process of polyclonal nature that can regress, in time and in the presence of immunodeficiency, it can progress to a true sarcoma. This is likely due to the long-lasting expression of HHV-8 latency genes in spindle cells associated with the deregulated expression of oncogenes and oncosuppressor genes and, for AIDS-KS, with the effects of the HIV-1 Tat protein.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11430595     DOI: 10.1016/s0065-230x(01)81005-8

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN: 0065-230X            Impact factor:   6.242


  27 in total

Review 1.  Molecular biology of KSHV in relation to AIDS-associated oncogenesis.

Authors:  Whitney Greene; Kurt Kuhne; Fengchun Ye; Jiguo Chen; Fuchun Zhou; Xiufen Lei; Shou-Jiang Gao
Journal:  Cancer Treat Res       Date:  2007

2.  Transcription pattern of human herpesvirus 8 open reading frame K3 in primary effusion lymphoma and Kaposi's sarcoma.

Authors:  P Rimessi; A Bonaccorsi; M Stürzl; M Fabris; E Brocca-Cofano; A Caputo; G Melucci-Vigo; M Falchi; A Cafaro; E Cassai; B Ensoli; P Monini
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

3.  Reactivation of Kaposi's sarcoma-associated herpesvirus from latency requires MEK/ERK, JNK and p38 multiple mitogen-activated protein kinase pathways.

Authors:  Jianping Xie; Adetola Olalekan Ajibade; Fengchun Ye; Kurt Kuhne; Shou-Jiang Gao
Journal:  Virology       Date:  2007-10-26       Impact factor: 3.616

4.  Murine gammaherpesvirus 68 ORF52 encodes a tegument protein required for virion morphogenesis in the cytoplasm.

Authors:  Eric Bortz; Lili Wang; Qingmei Jia; Ting-Ting Wu; Julian P Whitelegge; Hongyu Deng; Z Hong Zhou; Ren Sun
Journal:  J Virol       Date:  2007-07-18       Impact factor: 5.103

5.  Immune disorders and susceptibility to neoplasms.

Authors:  Om Prakash; Javed Gill; Gist Farr
Journal:  Ochsner J       Date:  2002

6.  A novel role of hydrogen peroxide in Kaposi sarcoma-associated herpesvirus reactivation.

Authors:  Fengchun Ye; Shou-Jiang Gao
Journal:  Cell Cycle       Date:  2011-10-01       Impact factor: 4.534

7.  Use of boosted protease inhibitors reduces Kaposi sarcoma incidence among male veterans with HIV infection.

Authors:  Marc A Kowalkowski; Jennifer R Kramer; Peter R Richardson; Insia Suteria; Elizabeth Y Chiao
Journal:  Clin Infect Dis       Date:  2015-01-13       Impact factor: 9.079

8.  Long-term-infected telomerase-immortalized endothelial cells: a model for Kaposi's sarcoma-associated herpesvirus latency in vitro and in vivo.

Authors:  Feng-Qi An; Hope Merlene Folarin; Nicole Compitello; Justin Roth; Stanton L Gerson; Keith R McCrae; Farnaz D Fakhari; Dirk P Dittmer; Rolf Renne
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

9.  Induction of angiogenic chemokine CCL2 by human herpesvirus 8 chemokine receptor.

Authors:  Young Bong Choi; John Nicholas
Journal:  Virology       Date:  2009-12-09       Impact factor: 3.616

10.  Viral inhibitor of apoptosis vFLIP/K13 protects endothelial cells against superoxide-induced cell death.

Authors:  Mathias Thurau; Gaby Marquardt; Nathalie Gonin-Laurent; Kristina Weinländer; Elisabeth Naschberger; Ramona Jochmann; Khaled R Alkharsah; Thomas F Schulz; Margot Thome; Frank Neipel; Michael Stürzl
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.